Skip to search formSkip to main contentSkip to account menu

EAA-090

Known as: EAA 090, Perzinfotel 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
OBJECTIVE To investigate the ability of perzinfotel (an N-methyl-d-aspartate receptor antagonist) and a proprietary phospholipase… 
2010
2010
OBJECTIVE To determine the effects of perzinfotel, butorphanol, and their combination on the minimal alveolar concentration (MAC… 
2009
2009
OBJECTIVE-To determine the effects of IV administration of perzinfotel and a perzinfotel-fentanyl combination on the minimum… 
2009
2009
Previous studies with perzinfotel (1), a potent, selective, competitive NMDA receptor antagonist, showed it to be efficacious in… 
2007
2007
OBJECTIVE To determine the effect of IV administration of perzinfotel on the minimum alveolar concentration (MAC) of isoflurane… 
2005
2005
Perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] is a selective, competitive N… 
2004
2004
Two novel N-methyl-d-aspartate (NMDA) antagonists with unique chemical structures, EAA-090 (2-[8,9-dioxo-2, 6-diazabicyclo[5.2.0… 
2002
2002
EAA-090 is a novel squaric acid amide derivative that has been identified as a potential treatment for the ischemic brain damage… 
1998
1998
The diazabicyclic amino acid phosphonate 15, [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid, was…